| Date | Title | Description | |
|---|---|---|---|
| 03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
| 16 Jul 2021 | On Corporate Governance | ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company | Download |
| 22 Jun 2021 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. | Download |
| 22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
| 29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 11 May 2022 | On Corporate Governance | The Company informs about the appointment of a new member in its Board of Directors | Download |
| 11 May 2022 | On business and financial situation | The Company releases the press release related to the first quarter 2022 financial result | Download |
| 11 May 2022 | On business and financial situation | The Company releases the first quarter 2022 financial results presentation | Download |
| 11 May 2022 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2022 General Shareholders Meeting | Download |
| 05 Apr 2022 | Liquidity and counterparty agreements | The Company communicates that it has entered into a liquidity agreement with Bestinver S.V., S.A. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Jul 2019 | R&D: new licenses, patents and registered trademarks | ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. | Download |
| 02 Jul 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2019 | Download |
| 26 Jun 2019 | Información sobre dividendos | The Company informs about the dividends payment | Download |
| 12 Jun 2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its General Shareholders Meeting | Download |
| 08 May 2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its 2019 General Shareholders Meeting | Download |